Role of the ErbB-2 receptor in DNA repair associated cisplatin resistance in non-small cell lung cancer cell lines
Jesse. Paterson · container not stated · 1998
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
· OpenAlex · dissertation · 1998
Abstract
Non-small cell lung cancer (N-SCLC) is characterized by intrinsic resistance (appearing without drug selection) to chemotherapy treatments. Molecular mechanism(s) of this type of resistance are not fully understood. Using a panel of N-SCLC cell lines, we have demonstrated that upregulation of DNA repair is due, at least in part, to an overexpression of the tyrosine kinase receptor erbB-2.
To explore the mechanism by which erbB-2 affects DNA repair regulation in N-SCLC, I examined the transcriptional regulation of three proteins involved in the early steps of the nucleotide excision repair (NER) pathway, namely XPA, XPB, and XPD, using vectors where a CAT gene was under the control of the promoter for each of the genes. The second part of my studies was to investigate the effect of potential novel inhibitors of DNA repair synthesis, termed ketonucleosides and keto-C-nucleosides, on cell killing of erbB-2 overexpressing cells compared to cells with low erbB-2.
The cytotoxicity and apoptotic induction ability of these drugs was measured in a panel of N-SCLC cell lines. (Abstract shortened by UMI.)
Open the resolved locator · 10.82308/37101
Metadata licence: OpenAlex metadata (CC0)